Skip to content

Impact of Guidelines on Cardiovascular and Economic Outcomes With Focus on Lipid Lowering Drugs

Predicted Impact on Cardiovascular and Economic Outcomes of Swedish Atherosclerotic Cardiovascular Disease Guideline 2014 With Focus on Lipid Lowering Treatment

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02929550
Acronym
GuLLD
Enrollment
5304
Registered
2016-10-11
Start date
2015-01-31
Completion date
2016-04-30
Last updated
2020-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Keywords

Cardiovascular disease, Costs, Guidelines, Lipids, Myocardial infarction

Brief summary

Methods: All patients \<75 years registered in the Swedish Secondary Prevention after Heart Intensive care Admission registry (SEPHIA), will be followed-up within one year post-myocardia infarction (MI). The REACH risk prediction and a calibrated model for recurrent cardiovascular disease (CVD) events and death will be used to estimate base case, and calibrated CVD outcomes based on gender-specific risk factors. The predicted impact of the LDL-C reduction on the risk of CVD will be based on Cholesterol Treatment Trialists´ Collaboration findings.

Detailed description

SWEDEHEART is a Swedish national registry consisting of several sub registries in which patients with acute coronary syndrome are prospectively registered. Patient characteristics, hospital treatments, drug treatments at discharge, and outcome for patients consecutively included and treated at all Swedish coronary care units are collected in this registry.SEPHIA is a sub registry collecting data on secondary prevention and cardiac rehabilitation. Follow-up are registered at six to ten weeks and at 12 to14 months post MI by office visits or phone. Around 80 % of all Swedish acute myocardial infarction (AMI) patients below the age of 75 years are included in this register. In this study, a cohort of 5 904 (74% men) registered in the SEPHIA registry and who had one year follow-up during 2013, will be included. Data are aggregated and delivered from the SWEDEHEART/SEPHIA national registry. All patients were informed about their participation in the registry, the follow-up, and their right to decline participation. No written consent was obtained

Interventions

OTHERWell-controlled

Both groups got treatment but well-controlled reached target of LDL-C\<1.8 mmol/l

Sponsors

Uppsala University
CollaboratorOTHER
Karolinska Institutet
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 74 Years
Healthy volunteers
No

Inclusion criteria

All patients with acute myocardial infarction registered in the SEPHIA registry and who had one year follow-up during 2013 -

Exclusion criteria

none \-

Design outcomes

Primary

MeasureTime frameDescription
Percentage of AMI patients who have achieved target goal of LDL-cholesterol 1.8 mmol/L or notAMI patients with one year follow-up year 2013Treatment gap will be analysed in well-controlled (LDL-C ≤1.8 mmol/L) and non-controlled ( LDL-C \>1.8 mmol/L) cohort in men and women separately.

Secondary

MeasureTime frameDescription
Number of predicted CVD events gained if target LDL-cholesterol was achieved in the non-controlled groupPredicted number of events within a 10 year periodNumber of events predicted to occur in the non-controlled group
Health care costs in SEK saved, due to number of predicted CVD events gained if target LDL-cholesterol was achieved in the non-controlled groupPredicted health care costs within a 10 year periodHealth care costs predicted to be gained if the non-controlled group achieved target LDL-cholesterol

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026